Gene signature predictive of response to chemotherapy in mCRC [array]

The objective is to generate a robust and validated predictor profile for chemotherapy response in patients with mCRC using microarray gene expression profiles of primary colorectal cancer tissue. To define a gene signature of response to chemotherapy in metastatic colorectal cancer, samples were obtained from 40 patients from Marques de Valdecilla Hospital who underwent primary surgery. Gene expression was detected and quantified using the Human Whole Genome U133 Plus 2.0 array (Affymetrix), containing 54675 human gene probes. Adequate RNA and microarray analysis were obtained from only 37 patients.

本研究旨在利用原发性结直肠癌组织的微阵列基因表达谱，构建针对转移性结直肠癌（metastatic colorectal cancer, mCRC）患者化疗应答的稳健且经过验证的预测特征谱。为明确转移性结直肠癌化疗应答的基因特征，研究从马尔克斯·德·巴尔德西利亚医院的40例接受原发性肿瘤切除术的患者中获取了样本。采用人类全基因组U133 Plus 2.0芯片（Affymetrix）对基因表达进行检测与定量，该芯片包含54675个人类基因探针。最终仅37例患者获得了合格的RNA样本及有效的微阵列分析数据。